Oncolojia Jumuishi
Tiba za Asili za Nyongeza kwa Matibabu ya Saratani
Tiba za asili mbadala zenye sifa za kupunguza maumivu, kupambana na uvimbe na kuimarisha kinga zinazopunguza dalili za saratani na kuongeza maisha.
Jinsi Tunavyofanya Kazi
Stage 3–4 cancer support
Immunostimulant therapies
Pain management
Quality of life improvement
Nutritional oncology support
Psychological support
Anza Safari Yako ya Kupona
Tuma historia yako ya matibabu na ripoti, na wataalamu wetu watafanya tathmini ya kesi yako na kupendekeza mpango maalum wa matibabu unaolingana na mahitaji yako.
Omba UshauriWhatsAppProgramu zetu za Matibabu kwa Muhtasari
Linganisha lengo, tiba muhimu, muda wa kukaa na wagombea wa kufaa katika programu kuu.
| Programu | Lengo Kuu | Tiba Muhimu / Ubunifu | Muda wa Kukaa | Mazingira ya Matibabu | Inafaa Kwa |
|---|---|---|---|---|---|
| Oncolojia Jumuishi | Msaada wa saratani ya hatua ya juu | CIMAvax-EGF®, VAXIRA®, HEBERSaVax®, VIDATOX® | Wiki 2–4 | Kulala na nje | Wagonjwa wa saratani hatua 3–4 |
| Urekebishaji wa Kimwili | Kupona kwa neva, mifupa na moyo/mapafu | NeuralCIM®, fizioterapia ya hali ya juu | Wiki 3–6 | Kulala kwa kini | Kiharusi, jeraha la ubongo, baada ya upasuaji |
| Matibabu ya Mguu wa Kisukari | Kidonda cha mguu wa kisukari na kuokoa mguu | Heberprot-P®, huduma ya hali ya juu ya vidonda | Wiki 2–6 | Kulala na nje | Vidonda vya kisukari, hatari ya gangreni |
| Ugunduzi wa Mapema wa Mshipa | Ugunduzi wa mapema wa hatari ya mishipa | Uchunguzi wa mishipa usio na upasuaji | Siku 2–5 | Uchunguzi wa nje | Uchunguzi kingizi wa moyo na mishipa |
| Hemodialyzi wakati wa Likizo | Huduma ya figo wakati wa safari | Hemodialisisi ya kisasa + nefrologia | Kwa kikao / endelevu | Kitengo cha dialisisi cha nje | Wagonjwa wa dialisisi wanaotembelea Cuba |
| Dawa ya Ayurveda | Uondoaji sumu wa kiutu na magonjwa sugu | Panchakarma, dawa za mimea, yoga | Wiki 2–3 | Makazi ya afya | Msongo, magonjwa sugu, uondoaji sumu |
| Ubora wa Maisha | Tathmini ya afya kingizi na ustarehe | Uchunguzi, upangaji wa mtindo wa maisha | Siku 3–7 | Tathmini za nje | Watu wazima wanaojali afya, uchunguzi wa mtendaji |
| Matibabu ya Utegemezi wa Dawa | Kurekebisha uraibu wa dawa na tabia | Uondoaji sumu, tiba ya akili na tabia | Wiki 4–8 | Kulala katika asili | Uraibu wa dawa na tabia |
Muda ni makisio; mpango wako maalum unathibitishwa baada ya ushauri wa matibabu.
Medical Evaluation Process
A clear, structured process guides you from first contact through to the completion of treatment.
1. Initial Consultation Request
Submit your medical records and treatment inquiry through our secure online consultation form. Our international patient coordinators review your case within 24 hours.
2. Specialist Medical Review
A board-certified specialist in the relevant discipline reviews your diagnosis, imaging, and laboratory results to determine suitability for the program.
3. Personalized Treatment Plan
Based on the review, our medical team develops an individualized treatment protocol with detailed timelines, therapies, and estimated costs.
4. Travel & Accommodation Coordination
Our concierge team handles visa support letters, flight coordination, airport transfers, and accommodation in partner hotels near the health center.
5. On-Arrival Assessment & Treatment
Upon arrival, a final in-person assessment confirms the plan. Treatment begins under continuous multidisciplinary medical supervision.
Treatment Duration
Treatment duration varies by program and individual patient needs. Most international medical programs at La Pradera range from 2 to 6 weeks, allowing sufficient time for comprehensive assessment, therapeutic intervention, and recovery monitoring. Your personalized treatment plan will include a precise estimated timeline after the specialist medical review.
Patient Eligibility
- Adults (18+) with a confirmed medical diagnosis appropriate for the selected program
- Completed medical records including recent imaging and laboratory results
- Medical clearance for international travel
- No uncontrolled acute conditions that would prevent safe treatment
- Willingness to comply with the prescribed treatment protocol and follow-up schedule
- Valid passport and ability to obtain a Cuban medical visa (support letter provided)
Why Choose Cuba for Medical Treatment
Accredited by Cuba's Ministry of Public Health (MINSAP)
Decades of experience treating international patients from over 40 countries
Pioneering Cuban biotechnology: CIMAvax-EGF®, Heberprot-P®, NeuralCIM®
Transparent, all-inclusive pricing with no hidden fees
Frequently Asked Questions
How do I begin my medical treatment in Cuba?
Begin by submitting a consultation request through our online form. Our international patient coordinators will review your medical records and connect you with the appropriate specialist within 24 hours to develop a personalized treatment plan.
Do I need a visa to travel to Cuba for medical treatment?
Yes. International patients require a Cuban medical visa. La Pradera provides an official invitation letter once your treatment plan is confirmed, which you submit with your visa application at the Cuban consulate in your country.
Is the treatment at La Pradera covered by international health insurance?
Coverage depends on your insurance provider and policy. We recommend contacting your insurer before travel. La Pradera provides detailed medical reports and invoices that you can submit for reimbursement. Direct payment options are also available.
What language support is available for international patients?
Our international patient services team provides interpretation in English, Spanish, Arabic, French, Russian, Turkish, and other languages. Medical consultations are conducted with professional interpreters to ensure clear communication throughout your treatment.
Can a family member or companion accompany me during treatment?
Yes. We encourage patients to travel with a companion. Accommodation can be arranged for family members in nearby partner hotels, and our concierge team assists with their travel and stay arrangements.
Explore Other Programs
Urekebishaji wa Kimwili
Urekebishaji wa kimwili wa kina, wa kina na maalum kwa watoto na watu wazima wenye hali za neva, upa
Learn moreUbora wa Maisha
Uzuiaji wa magonjwa na ugunduzi wa mapema kupitia tathmini za afya maalum. Tunakuza mitindo ya maish
Learn moreDawa ya Ayurveda
Sayansi ya Uhai — hekima ya kale yenye zaidi ya miaka 5,000 ya matumizi. Tiba zinazorekebisha usawa
Learn moreHemodialyzi wakati wa Likizo
Furahia likizo yako Cuba bila kukatisha matibabu ya hemodialyzi. Msaada kamili wa matibabu huhakikis
Learn moreAina za Saratani Tunazotibu
Taarifa za kina kuhusu hali mahususi zinazotibiwa katika programu yetu.
Muhtasari
Lung cancer is one of the most common and serious types of cancer worldwide. La Pradera offers treatment with CIMAvax-EGF®, the world's first therapeutic vaccine for non-small-cell lung cancer (NSCLC), developed by Cuba's Center of Molecular Immunology (CIM). Unlike preventive vaccines, CIMAvax-EGF® stimulates the patient's immune system to produce antibodies against epidermal growth factor (EGF), depriving cancer cells of the protein they need to multiply and grow.
Anayeweza Kupata Faida
Adults diagnosed with stage IIIB or IV non-small-cell lung cancer (NSCLC) who have completed or are completing first-line oncology treatment (chemotherapy or radiotherapy). The vaccine is used as maintenance therapy to help control tumor growth and extend survival.
Taratibu
After eligibility assessment, patients receive a series of intramuscular injections of CIMAvax-EGF® over a structured treatment protocol. The regimen begins with an induction phase of 5 doses in the first month, followed by monthly maintenance injections. Treatment is administered under continuous medical supervision with regular imaging and blood work to monitor response.
Faida
- Stimulates the body's own immune system to target cancer cells
- Low toxicity profile compared to conventional chemotherapy
- Outpatient administration — no hospitalization required for each dose
- Improves quality of life during maintenance phase
- Developed by Cuba's Center of Molecular Immunology with over a decade of clinical use
Matarishi
Not suitable for patients with small-cell lung cancer (SCLC), pregnant or breastfeeding women, patients with active autoimmune diseases, or those with severe uncontrolled medical conditions. A full medical evaluation determines eligibility.
Matokeo Yanayotarajiwa
Clinical studies indicate that CIMAvax-EGF® can slow disease progression and improve survival in eligible patients, particularly those with high EGF levels. Results vary by individual; the medical team provides a personalized prognosis after reviewing each case.
Ubunifu wa Matibabu wa Cuba
Programu za Matibabu · La Pradera
CIMAvax-EGF®
Chanjo ya tiba kwa saratani ya mapafu.
VAXIRA®
Chanjo ya tiba iliyotengenezwa na wanasayansi wa Cuba na Argentina.
HEBERSaVax®
Chanjo mpya ya tiba iliyotengenezwa na CIGB.
VIDATOX® 30CH
Dawa ya homeopathia kutokana na sumu ya nge buluu.
Marejeo ya Sayansi
- 1Rodríguez PC, et al. CIMAvax-EGF immunotherapy in advanced non-small cell lung cancer: Survival and immune response. Clinical Cancer Research.Chanzo: Center of Molecular Immunology (CIM)Tazama marejeo
- 2Rodríguez PC, et al. CIMAvax-EGF: A novel therapeutic vaccine for non-small-cell lung cancer. Journal of Clinical Oncology.Chanzo: Center of Molecular Immunology (CIM), Havana, CubaTazama marejeo
- 3Berlanga Acosta J, et al. Heberprot-P: Recombinant human epidermal growth factor for diabetic foot ulcers. International Wound Journal.Chanzo: Center for Genetic Engineering and Biotechnology (CIGB), Havana, CubaTazama marejeo
- 4Cuban Ministry of Public Health (MINSAP). National Health Statistics Annual Report.Chanzo: Ministry of Public Health of CubaTazama marejeo
Tunatumia cookies kuboresha uzoefu wako na kuchambua trafiki. Kwa kuendelea, unakubali matumizi ya cookies. Sera ya Faragha